Literature DB >> 9138385

[Acute drug-induced agranulocytosis: experience of the Regional Center of Pharmacovigilance of Lyon over 7 years].

T Vial1, C Pofilet, E Pham, C Payen, J C Evreux.   

Abstract

Sixty-two cases of drug-induced agranulocytosis, spontaneously reported to the regional drug monitoring centre in Lyon from 1988 to 1994, have been analysed. The mean age of patients was 58.6 years, and sex ratio was 1:1. The mean delay of onset was 46.2 days and absolute neutrophil counts (ANC) dropped below 0.1 x 10(9)/l in 73 per cent of patients. Bone marrow aspirates disclosed absence of myeloid series in 28 per cent of investigated cases. Neutrophil recovery occurred after a mean of 9.3 days, and the overall fatality rate was 6.5 per cent. Haematopoietic growth factors (HGF) were used in 11 patients with an ANC below 0.1 x 10(9)/l and/or a hypoplastic bone marrow. We have found no clear indication for a potential benefit of HGF treatment, but HGF were usually administered late during the course of neutropenia, i.e., after a mean of 6 days. The incidence rate estimated for people living in the Rhône administrative division was 3.3 per million per year, similar to that found in epidemiological studies. Drugs most frequently involved were anti-infective agents and psychotropic drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9138385

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  3 in total

1.  Incidence of agranulocytosis in Southwest France.

Authors:  Hélène Théophile; Bernard Bégaud; Karin Martin; Juan Ramon Laporte; Dolores Capella
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 2.  Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients.

Authors:  Emmanuel Andrès; Esther Noel; Jean-Emmanuel Kurtz; Nourredine Henoun Loukili; Georges Kaltenbach; Frédéric Maloisel
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 3.  Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids.

Authors:  Hervé Allain; Albert A Ramelet; Elisabeth Polard; Danièle Bentué-Ferrer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.